The actual benefit of GIOTRIF is substantial in the first-line therapy of locally advanced or metastatic non-small cell lung cancer with activating EGFR mutation(s).
Clinical Added Value
no clinical added value
GIOTRIF provides no improvement in actual benefit (level V, non-existent) in the first-line therapy of locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
Listen
